One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.

Masaharu Shinkai,Motohiro Ebisawa,Yasushi Fukushima, Satomi Takeuchi,Hiroshi Okada, Tatsuro Tokiyo,Nobuya Hayashi, Mami Takikawa,Gene Colice,Gun Almqvist

The Journal of asthma : official journal of the Association for the Care of Asthma（2023）

引用 7|浏览6

暂无评分

摘要

Tezepelumab 210 mg SC Q4W in Japanese patients with severe uncontrolled asthma showed safety/tolerability profiles similar to international data, with low exacerbation rates and improvements in lung function and asthma control.

查看译文

关键词

Biologic therapy,chronic respiratory disease,exacerbation,immunogenicity,lung function,open-label study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要